Nivolumab-Induced Thyroid Dysfunction

• Autori principali: Lohit Kumbar (Autore), Chitra Selvan (Autore), Y P Ganavi (Autore)
• Natura: Libro
• Pubblicazione: Wolters Kluwer Medknow Publications, 2021-01-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Nivolumab is one of human IgG4 monoclonal antibody belonging to the family of immune checkpoint inhibitors which acts by blocking ligand activation of programmed Cell death 1 receptor on T cells. Nivolumab has been approved for the management of patients with metastatic melanoma, metastatic squamous...